Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 2/2000

01-04-2000 | Questions and Answers

Questions and Answers

Published in: Drugs | Special Issue 2/2000

Login to get access

Excerpt

Question: Once initiated, antihypertensive drug therapy is usually lifelong, and there are clear clinical advantages to strategies that improve compliance, for example, once-daily therapy using a drug with a low adverse effect profile. Is there any evidence that increasing compliance reduces healthcare costs for patients with hypertension? …
Literature
1.
Gosse P, Dubourg O, Gueret P, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5mg versus enalapril 20mg: results of LIVE study [abstract]. J Am Coll Cardiol 1999; 33 Suppl. A: 246
Metadata
Title
Questions and Answers
Publication date
01-04-2000
Publisher
Springer International Publishing
Published in
Drugs / Issue Special Issue 2/2000
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200059002-00005

Other articles of this Special Issue 2/2000

Drugs 2/2000 Go to the issue

Review Article

Clinical Positioning of Indapamide Sustained Release 1.5mg in Management Protocols for Hypertension

Review Article

Pharmacoeconomic Considerations in the Management of Hypertension

Review Article

Diuretics as a Basis of Antihypertensive Therapy

Review Article

Pathoaetiology, Epidemiology and Diagnosis of Hypertension